Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iRhythm Technologies, Inc. - Common Stock (NQ:IRTC)

175.61 +1.80 (+1.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iRhythm Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
2 Healthcare Stocks to Research Further and 1 Facing Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
Centene, QuidelOrtho, iRhythm, and Bio-Techne Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations. 
Via StockStory
Topics Government World Trade
IRHYTHM TECHNOLOGIES INC (NASDAQ:IRTC) Combines Technical Strength and Growth Momentum
IRTC stock combines strong technical trends with accelerating fundamentals, aligning with Mark Minervini's high-growth strategy for potential continued gains. 
Via Chartmill
1 Cash-Producing Stock with Competitive Advantages and 2 We Question
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
How Is The Market Feeling About iRhythm Technologies?
 
Via Benzinga
Where iRhythm Technologies Stands With Analysts
 
Via Benzinga
Expert Outlook: iRhythm Technologies Through The Eyes Of 9 Analysts
 
Via Benzinga
1 Growth Stock to Add to Your Roster and 2 We Brush Off
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
IRHYTHM INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. – IRTC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
3 Overrated Stocks with Open Questions
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service
From iRhythm
Via GlobeNewswire
3 Unprofitable Stocks We Steer Clear Of
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
iRhythm Technologies to Participate in Upcoming Investor Conferences
From iRhythm
Via GlobeNewswire
This Figma Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
 
Via Benzinga
Investor Short Report Flags Steep Downside Risk For iRhythm Technologies
Spruce Point Capital warned iRhythm Technologies could face a 40%–70% stock decline, citing regulatory risks and product safety issues. 
Via Benzinga
AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority
From iRhythm
Via GlobeNewswire
Alignment Healthcare, Bio-Techne, Envista, iRhythm, and UFP Technologies Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
IRTC Q2 Deep Dive: Core Business Momentum and Product Expansion Shape Outlook
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 26.1% year on year to $186.7 million. The company’s... 
Via StockStory
Topics Artificial Intelligence Economy
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know
A number of stocks traded in opposite directions in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index... 
Via StockStory
Topics Bonds Economy Stocks
3 Unpopular Stocks We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
Topics Economy
iRhythm Technologies Inc (NASDAQ:IRTC) Fits Mark Minervini’s Trend-Following Strategy with Strong Technicals and Growth Momentum
iRhythm Technologies (IRTC) aligns with Mark Minervini's trend-following strategy, showing strong technicals, rising revenue, and earnings growth. A top performer in healthcare, IRTC is near its... 
Via Chartmill
iRhythm (IRTC) Stock Trades Up, Here Is Why
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 18% in the morning session after the company reported strong second-quarter earnings that surpassed analyst expectations... 
Via StockStory
Topics Artificial Intelligence
iRhythm (IRTC) Q2 Revenue Jumps 26%
Via The Motley Fool
Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
iRhythm (IRTC) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings Law Enforcement World Trade
Breaking Down iRhythm Technologies: 4 Analysts Share Their Views
 
Via Benzinga
iRhythm Technologies Inc (NASDAQ:IRTC) Q2 2025 Earnings: Revenue Beat and Narrower Loss Surprise Analysts
iRhythm Technologies (IRTC) reported Q2 2025 revenue of $186.69M, beating estimates, with a narrower loss of -$0.32 EPS. Stock remained steady post-earnings. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
iRhythm (NASDAQ:IRTC) Delivers Strong Q2 Numbers, Stock Soars
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 26.1% year on year to $186.7 million. The company’s... 
Via StockStory
iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions
From iRhythm
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.